Since its inception in 2003, the conference has been successfully held in kunming, haikou, guiyang, Harbin, guilin and xi 'an for 6 consecutive sessions, and its influence in the pharmaceutical industry is increasing day by day, becoming an annual industry event and building a bridge of communication between enterprises and government departments. This is the first time that the conference has been held in chongqing, and it is the organizers who value chongqing's strategic position in the western pharmaceutical industry. As partners of China medical science and technology achievements transformation center for many years, we have always adhered to the principle of complementary advantages and common development, and carried out extensive cooperation in new drug project development, technology transfer, investment and financing consultation, foreign exchange and other aspects, achieving good results. Different from previous conferences, in order to expand the popularity of the company in the industry, our company as a co-organizer of the conference to actively participate in it, and make full use of the opportunity of publicity and communication with peers. This not only reflects our good cooperation with the transformation center, but also shows the company's influence in chongqing and even the whole country.

During the conference, Mr. Li shugang, general manager of colun company, was invited by the conference organizer to give a report on the quality control of recombinant protein drug research and development at BBS. Based on more than 10 years of practical experience in the development of recombinant protein drugs, the report elaborates on the quality control issues related to the success or failure of drug development from a theoretical perspective. As we all know, the quality of drugs is related to the health quality of thousands of people, and is the basis of the survival of enterprises. In the current fierce market competition environment, the market competition is more product quality competition, therefore, put forward higher requirements for pharmaceutical research and development enterprises. While we are still blindly emphasizing the innovation of drug source, we should actively reflect on the key issue of drug quality control. Finally, general manager li pointed out in the report that there is a clear gap between the quality standards of many domestic drugs and those of foreign countries. In addition to the technical factors, the establishment of a public platform guided by government functional departments is crucial to improve the level of drug research and development, accelerate the industrialization process and improve the international competitiveness. The report was a complete success and was well received by participants. As another important topic of the conference -- project cooperation negotiation, our company Dr. Zhang wei made a project recommendation of a new drug recombinant human parathyroid hormone (1-84) (PTH). As an important product developed by the company, PTH is expected to become the most ideal drug for the treatment of osteoporosis, so it has been widely concerned by the industry since it obtained the clinical approval. The report makes a wonderful discussion on the technical features, market prospect and development progress of this project, and once again makes a good propaganda for PTH project. During the meeting, the company conducted in-depth communication with zhengda tianqing and other units on project cooperation.

Through participating in this conference, we deeply realized that with the rapid development of new drug creation technology, the development idea of "building cars behind closed doors" will be abandoned by The Times more and more. As a growing technology company, colun has always been based on its own development path, adhere to the establishment and improvement of existing technology platform, and seek various flexible cooperation opportunities with an open attitude to achieve the goal of leap-forward development of the company.